Candidates for medical therapy for the treatment of Peyronie's disease include those patients with early phase disease, those with unstable, progressive deformity or plaque, and those with painful erections. In addition, any patient who is not psychologically ready or interested in surgery, regardless of the duration or severity of disease, should also be considered a candidate for medical therapy. Medical treatment options include oral therapy with Vitamin E, Potaba, or colchicine and intralesional injection therapy with collagenase or calcium channel blockers. It should be noted, however, that virtually all of the early published studies on these medical therapies are¯awed due to low numbers of patients, short follow-up times, limited objective evaluation, and lack of proper control groups.
One commonly used oral therapy for the treatment of Peyronie's disease is Vitamin E. The rationale for its use is that as an anti-oxidant, Vitamin E prevents ®brosis. In 1945, Scott and Scardino established the popularity of this treatment when they reported a decrease in curvature in 78% and a decrease in plaque size in 91% of patients. 1 In 1974, Devine and Horton 2 reported an overall improvement in 60% of the 30 patients treated with Vitamin E. Furthermore, 20% noted resolution of plaque, 33% a straight penis, and 13% had no pain with sex. In 1992, at the NIH Conference on Peyronie's Disease, Devine and Snow presented their results on 105 patients receiving Vitamin E. In those patients, 99% noted reduction in pain, 13% reduction in bending, but 70% were unchanged. Overall, only 13% were found to be normal or improved with regard to sexual function and curvature. Therefore, Vitamin E is recommended because of its mild side effect pro®le and low cost, yet expectations for improvement with Vitamin E should be considered limited.
The rationale for oral therapy with Potaba (potassium aminobenzoate) is unclear but it has been proposed to cause increased utilization of oxygen by tissues, increase the activity of monamine oxidase, and/or decrease serotonin levels. In 1959, Zarafonetis and Horrax 3 reported that of 21 patients studied, 100% had reduction of pain, 82% had improved curvature, and 76% had resolution of plaque. In a recent review article, Wagenknecht 4 summarized data from 2752 patients treated with Potaba and reported a mean subjective improvement in 60% with a range of 10±82%. The FDA currently considers Potaba a`possibly effective' treatment although a prospective, double blind, multi-center study is clearly needed. The disadvantages of Potaba therapy are its cost at approximately $1000 per year and poor compliance due to GI upset.
Oral therapy with colchicine has been recently recognized as a potentially effective therapy. In 1992, Dominguez-Malagon et al 5 suggested the possible ef®cacy of oral colchicine in one patient with Peyronie's disease. In that one patient there was a reduction in plaque size and curvature. Akkus et al 6 in 1994, published a report on 24 patients in which 11% noted a slight decrease and 26% noted a marked decrease in curvature. No patients reported improvement in erection or hour-glass deformity and 78% noted reduction in pain. The proposed mechanisms of action for colchicine may be similar to that of calcium channel blockers, which will be discussed later. One question regarding colchicine use is whether systemic dosing provides an adequate concentration to the involved tunica albuginea. In my experience with over 30 patients, this drug is also poorly tolerated with about 50% experiencing GI upset.
The best studied intralesional therapy for the treatment of Peyronie's disease is the use of collagenase. The rationale for its use is that the primary extracellular matrix plaque component, collaga, will be degraded. In 1982, Gelbard et al, 7 reported that surgically excised plaques exposed to collagenase dissolved while elastin and vascular smooth muscle were spared. In 1985, Gelbard et al 8 performed the ®rst collagenase trial in 31 patients. This study also provided the ®rst objective measure of curvature change which was found to be reduced in 65% of the patients. In the ®rst placebo controlled, double blind study, Gelbard et al 9 reported on 49 patients receiving a single dose of collagenase which was based on the size and degree of bending by the Kelami classi®cation. Only those who had less than 30 of curvature and less than 2 cm of plaque noted substantial improvement. They concluded that the maximum angular decrease of only 15±20
was not`clinically signi®cant' and, therefore, best for patients with minimal disease. Currently, there is a multi-center, double blind, placebo controlled trial ongoing in the United States.
The use of intralesional Verapamil for the treatment of Peyronie's disease is based on the fact that exocytosis of extracellular matrix (ECM) collagen is a calcium-dependent process. Fibroblasts exposed to calcium channel blockers (CCB) undergo a phenotypic change in which collagen synthesis and secretion are reduced. Also, ECM collagenase activity is increased. More recent in vitro studies have demonstrated that CCB modify the expression of cytokines involved in wound healing. In 1994, Levine et al 10 reported on 14 patients receiving intralesional Verapamil injection. This was a noncontrolled, dose escalation trial with injection every two weeks for twelve injections up to a maximum dose of 10 mg. Pain was noted to decreased in 91%, hour-glass deformity subjectively improved in 100%, objective measures of curvature improved in 42%, and sexual function improved in 58%. In 1995, Arena et al 11 found that pain decreased in 91% and rigidity improved in 23% of 39 patients receiving intralesional injection of 10 mg of Verapamil every two weeks for six months. Curvature was noted to improve in 50% of patients with a duration of disease less than one year while only 10% improved with a duration greater than one year. At the 1996 International Society of Impotence Research (ISIR) meeting, Teloken et al 12 reported on 36 patients undergoing perilesional injection therapy of either saline, steroid, or 10 mg of Verapamil injected weekly for six weeks. They found no advantage to Verapamil therapy with a 30% correction in curvature in all groups. Also at the 1996 ISIR and AUA meetings, Levine reported on 38 patients completing intralesional Verapamil treatment. Ten mg of Verapamil was injected every 2±4 weeks for a total of 12 injections. There was a rapid reduction in pain in 97% of the patients, improved subjective curvature in 76%, diminished shaft narrowing in 86%, improved distal rigidity in 93%, and improved sexual performance in 72%. Objective results were obtained in 35 of the 38 patients through dynamic duplex ultrasonography. While duplex vascular ow parameters did not change, curvature was noted to decrease in 54% and increase in 11%. Interestingly, plaque volume was noted to increase in 43%, but over time (6±18 months) there was a gradual decrease in palpable plaque. Furthermore, the patients were divided by Kelami classi®cation and, overall, there was no signi®cant difference between groups based on volume of plaque and degree of curvature. In 65% of those patients with a duration of disease less than one year, curvature decreased by a mean of 21 , while in 44% of those with greater than one year disease duration had a mean decrease in curvature of 23
. There is now a mean follow-up time of 24 months with no recurrence of deformity. Complication or side effects in this population were minimal with no infection, hypotension or arrhythmia noted. 13 
Conclusions
Therapeutic advances have not resulted in a reliable cure for Peyronie's disease. Recent advances in the understanding of wound healing may offer new treatments, such as modi®ers of cytokine and ®broblast function. Multiple modality therapy, such as intralesional Verapamil and collagenase plus concomitant oral treatment with colchicine, may be the best option for those patients who are not considered surgical candidates. Certainly, surgery remains an option for non-responders as well as those men with severe deformity, extensive calci®-cation, erectile failure or those who desire a rapid resolution to their penile deformity.
